[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606350":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":26,"locations":34,"responsibleParty":47,"collaborators":50,"id":60,"slug":26,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":26,"enrollmentInfo":68,"targetDuration":26,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":26,"overallStatus":83,"whyStopped":26,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Stanford University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cilostazol 100mg","EXPERIMENTAL","Participants take oral cilostazol until a study endpoint occurs, they reach maximum follow up duration (4 years), the participant withdraws, or the study ends.",[13],"Drug: Cilostazol 100 mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants take oral placebo until a study endpoint occurs, they reach maximum follow up duration (4 years), the participant withdraws, or the study ends.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Cilostazol 100 mg","Cilostazol 100 mg tablet taken orally twice daily following an initial 2-week period during which cilostazol is dosed at 100 mg tablet taken orally once daily to maximize tolerability.",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Placebo 100 mg tablet twice taken orally daily following an initial 2-week period during which placebo is dosed at 100 mg taken orally once daily to maximize tolerability.",[15],[31],{"name":32,"affiliation":5,"role":33},"Maarten Lansberg, MD, PhD","PRINCIPAL_INVESTIGATOR",[35],{"facility":5,"status":26,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":26},"Stanford","California","94305","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-122.16608,37.42411,{"lat":45,"lon":44},{"type":33,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Maarten Lansberg","Professor of Neurology",[51,54,56,58],{"name":52,"class":53},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",{"name":55,"class":6},"Yale University",{"name":57,"class":6},"University of Cincinnati",{"name":59,"class":6},"Medical University of South Carolina","100606350",false,"NCT07174414","Cilostazol for Prevention of Recurrent Stroke Trial","Clarity","Inclusion Criteria:\n\n* Diagnosis of stroke or mini-stroke (also called TIA) within the last 180 days\n* Currently taking aspirin or clopidogrel (not both) to prevent another stroke\n\nExclusion Criteria:\n\n* Had a spontaneous brain bleed within the last 2 years.\n* Moderate to severe heart failure.\n* Life expectancy is less than 6 months.","ALL","40 Years",{"count":69,"type":70},2000,"ESTIMATED","INTERVENTIONAL",[73],"PHASE3","The goal of this clinical trial is to learn whether adding cilostazol to aspirin or clopidogrel prevents stroke and heart attack in people who have had a stroke or mini-stroke.",[76,77,78,79,80,81,82],"Stroke Recurrence","Myocardial Infarction","Vascular Death","Ischemic Stroke","TIA (Transient Ischemic Attack)","Stroke (CVA) or Transient Ischemic Attack","Recurrent Stroke","NOT_YET_RECRUITING","2025-09-12",{"date":86,"type":87},"2025-09-16","ACTUAL",{"date":89,"type":70},"2026-08",{"date":91,"type":70},"2031-07",{"name":5,"class":6},1]